26 citations
,
May 2014 in “BioEssays” This review discusses how neuroendocrine pathways influence keratin regulation in human skin and hair follicles and suggests these pathways as potential targets for new treatments of skin disorders, but reports no clinical results.
7 citations
,
June 2021 in “Trends in Food Science and Technology” This commentary reviews potential dietary and mineral influences on androgenetic alopecia and suggests considering a diet low in cholesterol and glycaemic index with improved glucose control and magnesium fortification, without new clinical results.
2 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” This study found that Hataedock may alleviate atopic dermatitis symptoms in mice by maintaining skin homeostasis and improving skin barrier formation through the endocannabinoid system.
January 2026 in “International Journal of Molecular Sciences” This review discusses the diverse industrial applications of hemp beyond traditional fiber uses, highlighting its phytochemical components with antioxidant and antimicrobial properties that are explored in agrochemicals, cosmetics, and food sectors.
November 2025 in “International Journal of Applied and Experimental Biology” In this review, the authors discussed the potential of hemp in cosmeceutics for skin conditions like acne and dermatitis, emphasizing its therapeutic properties and formulation challenges but noting the need for standardizing cannabinoid content and documenting effectiveness.
March 2025 in “Journal of Dermatological Treatment” In this case report, a patient required more local anesthetic than usual for hair transplant surgery, which the authors suggest may be due to cannabis use impacting pain sensitivity and anesthetic clearance.
October 2024 in “Aesthetic Cosmetology and Medicine” This study examined the potential benefits of incorporating cannabis-derived compounds like cannabidiol and seed oil into skincare products, finding they may improve skin health and address inflammation and dermatological issues, thus supporting their role in developing effective cosmeceuticals.
July 2024 in “Medical alphabet” In this review, researchers discuss the factors contributing to early graying, such as genetic predisposition, oxidative stress imbalance, and nutrient deficiencies, and highlight potential restoration methods involving palmitoyl tetrapeptide-20 and the endocannabinoid system in hair follicles.
February 2024 in “Skin health and disease” This source reviews popular cosmeceutical ingredients for skin care, noting that while they are popular among consumers for anti-aging benefits, many lack robust clinical evidence for their efficacy and safety, as they are not regulated by the FDA.
January 2023 in “IGI Global eBooks” This review covers the diverse applications of Cannabis sativa in areas like cancer treatment, skin care, and alopecia, but reports no new clinical results; continued research faces challenges due to legal variability.
August 2021 in “Journal of cosmetic dermatology” This issue of the Journal of Cosmetic Dermatology reviews several topics, including the use of radiofrequency in aesthetics and cannabinoids for skin diseases, but presents no new research findings.
January 2017 in “Springer eBooks” The document concludes that scalp health is influenced by complex factors affecting sebaceous glands, including hormones, aging, and various substances.
May 2008 in “University of Debrecen Electronic Archive (University of Debrecen)” This study examined both human and mouse follicles, finding that cannabinoid and TRPV1 systems independently regulate hair follicle biological functions, impacting hair growth and development.
March 2022 in “Research Square (Research Square)” This case report describes a 15-year-old girl with Alopecia Universalis and psychiatric conditions experiencing hair regrowth after self-medicating with cannabis, suggesting it may have therapeutic potential.
December 2018 in “IntechOpen eBooks” This review discusses recent advancements in understanding neuroendocrine regulation of keratin biology and highlights the potential of neurohormones to treat skin disorders, but it reports no new clinical results.
11 citations
,
October 2020 in “General and comparative endocrinology” This study found that age-related fluctuations in hormones and endocannabinoids in male C57BL/6 mice showed specific patterns, with peak values observed around 2.7 to 3.4 months, with these patterns seen in both plasma and hair but with different magnitudes.
1 citations
,
January 2013 in “Journal of Investigative Dermatology” The document concludes that stem cells and their environments are crucial for skin and hair health and have potential for medical treatments.
April 2023 in “Journal of Investigative Dermatology” This study found an increased number of perivascular mast cells and upregulated CB1 expression in patients with IgA vasculitis compared to healthy individuals, suggesting potential involvement in the disease's pathogenesis and inflammation.
January 2015 in “Elsevier eBooks” This study suggests that targeting the endocannabinoid system through pharmacological interventions may help reduce compulsive hair-pulling in individuals with trichotillomania.
1 citations
,
May 2024 in “Pharmaceutics” This review discusses the potential benefits and challenges of using hemp actives like cannabinoids, terpenes, and flavonoids in skincare products, emphasizing their anti-inflammatory, antimicrobial, and antioxidant properties and strategies to enhance their penetration and integration in natural and sustainable cosmeceuticals.
18 citations
,
April 2024 in “Phytotherapy Research” This review examines the potential of plant-derived compounds like quercetin, curcumin, EGCG, apigenin, and cannabinoids for treating neurodegenerative disorders, while discussing their benefits and limitations, and calls for more extensive pre-clinical and clinical research.
14 citations
,
January 2017 in “Elsevier eBooks” This review explores cannabigerol (CBG) as a potential therapeutic agent with various pharmacological activities but reports no new clinical results, emphasizing the need for further research on its efficacy and safety.
7 citations
,
October 2023 in “European Journal of Pharmacology” This study found that Cannabidivarin (CBDV) promotes neuronal differentiation and inhibits oligodendrocyte maturation via TRPV1 modulation, highlighting its potential in neural stem cell research.
May 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that Cannabidivarin (CBDV) promotes neuronal survival, proliferation, and differentiation via TRPV1 activation but inhibits oligodendrocyte differentiation in postnatal neurogenesis.
9 citations
,
April 2024 in “Metabolites” This study reviews the current research on the metabolomic profile and antimicrobial properties of the Cannabis plant, highlighting its effective antibacterial activity against multidrug-resistant bacteria while noting a lack of studies on its impact on plant and aquatic pathogens, emphasizing potential agricultural benefits.
November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” This case report from the University of Alabama describes a rare paradoxical effect where divalproex sodium was associated with increased agitation and hostility in a patient with schizoaffective disorder.
2 citations
,
March 2022 in “Journal of Personalized Medicine” Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
1 citations
,
January 2021 in “Journal of the Dermatology Nurses’ Association” This article discusses various dermatological topics from the 2020 Dermatology Nurses' Association annual meeting held online, highlighting updates on skin conditions and treatments without reporting new clinical results.
September 2024 in “Actas Dermo-Sifiliográficas” This study discusses trichodynia, a painful scalp condition often linked to various forms of alopecia and psychiatric comorbidities, highlighting its clinical diagnosis, lack of specific treatments, and suggesting the need for more research to explore effective therapies.
January 2024 in “Wiadomości Lekarskie” This presentation explored recent developments in treating alcohol, opioid, and cannabis addiction, highlighting promising pharmacological and behavioral therapies, such as extended-release naltrexone for alcohol use and long-acting buprenorphine for opioids, alongside emerging strategies for cannabis use disorder.